Tandem Diabetes Care (TNDM) Expected to Announce Earnings on Thursday

Tandem Diabetes Care (NASDAQ:TNDM) is expected to be issuing its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $277.1440 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

Tandem Diabetes Care Stock Up 1.4%

TNDM stock opened at $18.95 on Tuesday. The stock’s 50 day simple moving average is $20.98 and its 200 day simple moving average is $16.90. The company has a market cap of $1.28 billion, a P/E ratio of -6.21 and a beta of 1.68. The company has a debt-to-equity ratio of 2.33, a quick ratio of 1.90 and a current ratio of 2.44. Tandem Diabetes Care has a fifty-two week low of $9.98 and a fifty-two week high of $35.12.

Institutional Trading of Tandem Diabetes Care

A number of institutional investors and hedge funds have recently modified their holdings of TNDM. Caitong International Asset Management Co. Ltd boosted its position in Tandem Diabetes Care by 200.0% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,205 shares of the medical device company’s stock worth $27,000 after purchasing an additional 1,470 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Tandem Diabetes Care by 80.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,330 shares of the medical device company’s stock worth $30,000 after purchasing an additional 593 shares during the period. Quarry LP raised its stake in shares of Tandem Diabetes Care by 2,597.1% during the 3rd quarter. Quarry LP now owns 3,695 shares of the medical device company’s stock worth $45,000 after purchasing an additional 3,558 shares during the period. Van ECK Associates Corp boosted its holdings in shares of Tandem Diabetes Care by 67.4% in the 4th quarter. Van ECK Associates Corp now owns 3,430 shares of the medical device company’s stock worth $75,000 after buying an additional 1,381 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Tandem Diabetes Care by 218.6% during the second quarter. Tower Research Capital LLC TRC now owns 9,168 shares of the medical device company’s stock valued at $171,000 after buying an additional 6,290 shares during the period.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Truist Financial set a $24.00 target price on Tandem Diabetes Care and gave the stock a “hold” rating in a research report on Thursday, December 18th. Sanford C. Bernstein restated a “market perform” rating and set a $25.00 price objective (up previously from $18.00) on shares of Tandem Diabetes Care in a report on Friday, January 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tandem Diabetes Care in a research note on Wednesday, January 21st. The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 target price on shares of Tandem Diabetes Care in a research report on Friday, January 9th. Finally, Mizuho upped their target price on shares of Tandem Diabetes Care from $18.00 to $21.00 and gave the stock a “neutral” rating in a report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $24.35.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.